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Exposure to Human and Bovine Noroviruses in a Birth Cohort in
Southern India from 2002 to 2006
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Mary K. Estes,c Gagandeep Kanga
Department of Gastrointestinal Sciences, Christian Medical College, Vellore, Indiaa; Department of Biostatistics, Christian Medical College, Vellore, Indiab; Department of
Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USAc
Human and bovine norovirus virus-like particles were used to evaluate antibodies in Indian children at ages 6 and 36months
and their mothers. Antibodies to genogroup II viruses were acquired early and were more prevalent than antibodies to geno-
group I. Low levels of IgG antibodies against bovine noroviruses indicate possible zoonotic transmission.
Noroviruses (NoVs) are nonenveloped, single-stranded posi-tive-sense RNA viruses, accounting for 50% of gastroen-
teritis outbreaks worldwide (1). Seroepidemiological surveys us-
ing NoV virus-like particles (VLPs) as antigens show exposure to
NoVs across the globe (2–7), with high seroprevalence in children
5 years of age; seroprevalence can reach 100% in adults (2, 8, 9).
Analyses of bovine strains suggest close relation to human NoV
genogroup I (GI) and GII.3 strains (10–14). Studies from the
Netherlands found that 22% of the population had antibodies to
bovine NoV, with veterinarians having high frequencies of anti-
bodies (15), raising the possibility of zoonotic transmission (16).
In this study, sera from children in a birth cohort and their moth-
ers were used to assess exposure to human and bovine norovirus
genogroups in early life and adulthood.
The study population was a birth cohort from semiurban
slums in Vellore, South India, recruited and monitored from 2002
to 2006, with sample collection as previously described (17–19).
Maternal sera at delivery and sera from children at 6 and 36
months were tested for IgG antibodies against human and bovine
viruses. Diarrheal samples from calves were collected from a vet-
erinary clinic and a commercial dairy farm in 2007 and 2008 (20).
Written informed consent was obtained from parents of all chil-
dren; the study was approved by the Institutional Review Board of
the Christian Medical College, Vellore, India.
The NoV GIII and NB VLPs were obtained from Linda Saif,
Ohio State University (21). Validation assays were carried out
prior to use of bovine VLPs using 20 bovine sera from a veterinary
clinic. Goat anti-bovine IgG-horseradish peroxidase (IgG-HRP;
(Jackson ImmunoResearch Inc., United States) was added, fol-
lowed by addition of 3,3=,5,5=-tetramethylbenzidine substrate so-
lution. The reaction was stopped with 2 M sulfuric acid after 15
min, and optical density (OD) was measured at 450 nm.
Serum IgG was detected using plates coated overnight with 2
g/ml of human and bovine VLPs in phosphate-buffered saline
(PBS) at 4°C, and the plates were blocked using 10% skim milk in
PBS. Diluted serum samples were added to uncoated and VLP-
coated wells and incubated. Anti-human IgG (Southern Biotech,
United States) was added, followed by goat anti-mouse IgG-HRP
(human adsorbed; Southern Biotech) and the substrate 2,2=-
azino-di(3-ethylbenzthiazoline-6-sulfonate) solution; the reac-
tion was stopped using 1% SDS solution, and OD was measured at
405 nm.
The assays for human and bovine VLPs differed in the stan-
dards and controls included on each plate. The GI and GII stan-
dard curves were 2-fold dilutions of positive human sera starting
at a 1:100 dilution, and the GIII and Nebraska bovine (NB) viruses
used 2-fold dilutions of purified human IgG (Sigma-Aldrich,
United States) starting at a 2-g/ml concentration. The mean ODs
for standards, controls, and samples were calculated if the differ-
ence between replicates was an OD of0.1. If the margin of error
for the internal reference included on every plate was more than
15% from the expected value, the plates were rejected.
Viral RNA was extracted from stool samples available from
children positive for serum antibodies against bovine NoVs, by
the guanidium isothiocyanate-silica method (22). Bovine diar-
rheal samples were additionally subjected to CF11 purification
(23). cDNA was generated by reverse transcription in the presence
of hexamers (Pharmacia Biotech, United Kingdom). Primers spe-
cific to NoV GIII and NB were used (24), and amplification was
detected on a 2% agarose gel.
Data were imported into GraphPad Prism, version 4.03. The
serum used for the standard curve was assigned an arbitrary value
of 0.25. The lowest serum IgG concentration that could be calcu-
lated from the linear portion of the standard curve was used as a
cutoff. Net absorbance was calculated by subtracting the negative-
well OD from the test well OD. The net absorbance for each of the
VLPs was plotted by Spearman’s rank correlation (rs) with a 95%
significance level to assess the possibility of IgG cross-reactivity by
STATA 10.0 (STATA Corp., United States) (15).
Enzyme-linked immunosorbent assay (ELISA) validation of
the bovine sera showed 90% (18/20) and 85% (17/20) positivity
for NoV GIII and NB antibodies, respectively. Among 6- and 36-
month-old children, seroconversion patterns suggest a lower level
of exposure to GI than GII (Fig. 1; Table 1), and the geometric
mean concentration (GMC) for NB was higher than for NoV GIII
(Table 1).
Cross-reactivity between VLPs was checked using Spearman’s
rank correlations. NoV GIII was positively correlated with NoV
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GI and NoV GII, indicating partial cross-reactivity. NB negatively
correlated with NoV GI and NoV GII, indicating a greater speci-
ficity. Positive correlation between NoV GI and GII indicates par-
tial cross-reactivity (Fig. 2). The GI and GII VLPs previously eval-
uated for specificity using the antisera prepared against the
expressed VLPs showed that they were antigenically distinct (25).
Studies have also shown the specificity of GIII and NB VLPs, with
no cross-reactivity observed with GI and GII with the antiserum
reagents produced (21, 26). Sequence comparison has shown a
low level of amino acid sequence identity between human and
bovine norovirus strains, suggesting that antigenically and genet-
ically, the strains are distinct (27). But cross-reactivity cannot be
completely ruled out, as limited antigenic cross-reactivity between
NoVs of different genogroups may occur, as evidenced by the use
of VLPs and antisera generated from panels of NoV genotypes of
genogroups I and II (28).
Of the 249 animal samples screened, one was positive for NoV
GIII. Sequence analysis by BLAST (http://blast.ncbi.nlm.nih.gov
/Blast.cgi) showed 81% identity to a GIII.1 bovine norovirus (Aba
Z5/2002/HUN, EU360814.1). No samples were positive for NB
virus. Of 99 stool samples from children screened for NoV GIII, 1
sample was positive by PCR but failed sequencing. No samples
were positive for NB norovirus.
The analysis of sera from infants at 6 months, when maternal
antibodies are expected to have waned, provides a baseline from
which an increase can be used to demonstrate exposure to noro-
viruses in early life. The inclusion of mothers’ sera allowed com-
parison with adults living in a similar environment. Antibodies to
genogroup II are acquired rapidly in early life, with at least 20% of
children seroconverting between 6 and 36 months, while rates of
acquisition of antibodies are lower for genogroup I. The antibody
acquisition rate is best documented for pediatric populations but
varies among adults and countries (5, 7, 9, 29–32) (Table 2).
Among adults, the prevalence of antibody to bovine norovirus
was lower (NoV GIII, 10.7%) than 20% and 26.7%, rates reported
in Europe (15, 33). The low value of Spearman’s rank correlation
indicated a moderate cross-reactivity of antibodies against NoV
GIII to NoV GI and GII, but this alone could not explain the
observed seroreactivity to bovine VLPs. This is similar to other
studies which show limited cross-reactivity between human and
bovine NoV strains (14, 15, 21, 34). The differences in the preva-
lence rates of antibody to the VLPs tested likely indicate different
levels of exposure to these viruses, with significant differences in
FIG 1 Seroconversion data of mothers (MS) and children at the ages of 6 and 36 months for NoV GI (A) and GII (B).
TABLE 1 Prevalence and geometric mean concentration of IgG
antibodies to VLPs of noroviruses GI, GII, and GIII and NB virus in
serum samples obtained from children at 6 and 36 months of age and
their mothers in a southern Indian urban community birth cohort study
Serum source VLP
No. with IgG
(% positive) GMC
95%
confidence
interval
Mothers NoV GI 73 (31.9) 25.43 21.79–29.68
NoV GII 175 (61) 52.46 47.20–58.32
NoV GIII 33 (10.7) 0.56 0.50–0.62
NB 1 (0.4) 1.1
6-mo-old children NoV GI 22 (9.6) 9.55 8.20–11.20
NoV GII 20 (7) 9.72 7.94–11.90
NoV GIII 1 (0.3) 0.29 0.26–0.31
NB 7 (2.6) 7.25 2.93–17.96
36-mo-old children NoV GI 25 (10.9) 12.73 10.41–15.57
NoV GII 77 (26.8) 32.29 27.06–37.53
NoV GIII 24 (7.8) 0.41 0.38–0.45
NB 12 (4.4) 2.95 1.20–4.37
Menon et al.
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FIG 2 Scatter plot of the absorbance values at 405 nm for serum IgG reactivity against NoV GI, GII, GIII, and NB in the tested sera. Spearman correlation
coefficient is calculated to check for cross-reactivity between the different norovirus genogroups.
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exposure between human genogroups and bovine NoVs. The
prevalence of antibodies against the bovine noroviruses indicates
either cross-reactivity or possible zoonotic transmission, but no
direct evidence was found by screening of human and bovine stool
samples. These studies broaden our understanding of NoV epide-
miology and highlight the importance of sequential samples to
determine exposure at the individual and population levels.
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